Purilogics Awarded Competitive Grant from the National Institute of Health - June 10 2019

Purilogics has been awarded an NIH Small Business Innovation Research (SBIR) Phase I grant for $220,772 to commercialize novel lentiviral vector affinity membrane chromatography technology. Gene therapy is one of the most promising therapeutic modalities to treat and cure diseases with limited or no alternative treatment options. Lentiviral vectors are emerging as one of the favored gene-delivery vehicles in clinical trials. The goal of this SBIR Phase I project is to develop an affinity membrane chromatography product for the rapid purification and efficient recovery of lentiviral vectors from vector cell supernatant. Purilogics has initiated collaborations with multiple stakeholders in the biopharmaceutical industry. These products will contribute to improving human health by enabling scalable production of the vectors that are needed for this emerging field of medicine.

About HHS SBIR program: HHS SBIR and STTR programs are an integral source of capital for early stage U.S. small businesses that are creating innovative technologies to improve health. These programs help small businesses break into the federal research and development (R&D) arena, create life-saving technologies, and stimulate economic growth. Please see details at https://sbir.nih.gov/about

The feed photo is downloaded from Dreamstime.com (Photo 85595022 © Stiggdriver).

Purilogics LLC